MonoPure™ also offers consumers the ability to get more bioavailable doses of omega-3 EPA + DHA in smaller softgels than with the EE form or reduce the number of softgels to be taken per day. This easy-to-swallow, easy-to-digest and highly absorbable omega-3 supplement means patients are more likely to take their practitioner-recommended dose and achieve the health benefits they are looking for.
XYMOGEN CEO and Founder Brian Blackburn said this breakthrough omega-3 technology is the only one of its kind being offered in the US and is exclusively offered by XYMOGEN. Thanks to a partnership with NEPTUNE WELLNESS SOLUTIONS, owners of an exclusive commercial license from INGENUTRA, the architects behind the MaxSimil® technology, the main ingredient in our MonoPure product line, XYMOGEN is again leading the industry with its innovation.
"We are always looking for ways to make the best products that give consumers the highest health benefits," Blackburn said. "NEPTUNE's patented technology mimics the biological digestive process and delivers a predigested and absorption-ready monoglyceride omega-3 fish oil. Omega-3 fatty acids have been studied extensively and found to have extremely positive effects on overall health."
The introduction of MonoPure™ into the market means more than just providing patients the convenience of swallowing fewer and in some cases smaller capsules. It also means patients' bodies can access the essential fatty acids in a much more efficient way, including patients with malabsorption conditions or compromised digestive health. Patients suffering from these types of conditions can, for example, include the elderly, celiac or cystic fibrosis patients, those with gallstones or chronic pancreatitis among others.
François-Karl Brouillette, Vice President Scientific Affairs at NEPTUNE believes MaxSimil® technology to be a true revolution in dietary fat absorption: "Our patented and clinically researched MaxSimil® technology makes the delivery of pre-digested and readily absorbable healthy fats now possible. This will make omega-3 supplements even more accessible, improving the overall health of a larger portion of the population."
In its quest to be an exemplary corporate citizen, XYMOGEN is also proud to highlight that MaxSimil® omega-3 fish oils are manufactured from marine oils originating from fish caught in ecologically responsible fisheries.
The complete line of MonoPure™ formulas includes Omega MonoPure 650 EC made of 650 mg of MaxSimil® fish oil omega-3 concentrate providing 300 mg of EPA, and 130 mg of DHA per softgel; Omega MonoPure MD EC made of 500 mg of MaxSimil® fish oil omega-3 concentrate providing 230 mg of EPA, 100 mg of DHA, and 50 mg of Arthricor® olive extract per softgel; and Omega MonoPure 1300 EC made of 1.3 g of MaxSimil® fish oil omega-3 concentrate providing 600 mg of EPA and 260 mg of DHA per softgel.
To learn more about XYMOGEN, a family-owned health sciences company, and its community involvement, research, distribution and products, visit XYMOGEN.com, email email@example.com or call 800-647-6100.
NEPTUNE WELLNESS SOLUTIONS is a nutrition products company focused on the business of customized unique nutrition solutions and specialty ingredients. The company develops turnkey solutions available in various unique delivery forms. Neptune also offers a variety of specialty ingredients, including premium krill oil manufactured in our state-of-the art facility and a variety of other marine oils, seed oils and specialty ingredients.
INGENUTRA™ is an ingredient technology company focused on developing, manufacturing, and commercializing scientifically validated, natural active ingredients that aim to improve human and animal health. It's MaxSimil® novel and patented delivery platform is based on technology that naturally enhances the absorption of lipid-based and lipid-soluble nutraceutical and pharmaceutical actives, such as omega-3s.
Distributed by Sara Brady Public Relations, Inc.
222 W. Comstock Avenue, Suite 215
Winter Park, Florida 32789
* Unpublished double-blind crossover pharmacokinetic clinical study comparing absorption of EPA+DHA in blood plasma between a regular ethyl ester (EE) fish oil and MaxSimil® enhanced fish oil.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/xymogens-omega-monopure-delivers-three-times-more-bioavailable-omega-3s-than-other-products-on-the-market-300339046.html